A Phase 1 Study to Evaluate the Effect of BCX7353 on the Single Dose Pharmacokinetics of the P-gp Substrate Digoxin and the BCRP Substrate Rosuvastatin and the Effect of the P-gp Inhibitor Cyclosporine on the Single Dose Pharmacokinetics of BCX7353
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Berotralstat (Primary) ; Ciclosporin; Digoxin; Rosuvastatin
- Indications Hereditary angioedema
- Focus Pharmacokinetics
- Sponsors BioCryst Pharmaceuticals
- 24 Oct 2017 Status changed from active, no longer recruiting to completed.
- 04 May 2017 New trial record